1. Home
  2. MDBH vs ALXO Comparison

MDBH vs ALXO Comparison

Compare MDBH & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDBH
  • ALXO
  • Stock Information
  • Founded
  • MDBH 1997
  • ALXO 2015
  • Country
  • MDBH United States
  • ALXO United States
  • Employees
  • MDBH N/A
  • ALXO N/A
  • Industry
  • MDBH
  • ALXO Biotechnology: Pharmaceutical Preparations
  • Sector
  • MDBH
  • ALXO Health Care
  • Exchange
  • MDBH Nasdaq
  • ALXO Nasdaq
  • Market Cap
  • MDBH 70.3M
  • ALXO 81.1M
  • IPO Year
  • MDBH 2023
  • ALXO 2020
  • Fundamental
  • Price
  • MDBH $8.09
  • ALXO $1.41
  • Analyst Decision
  • MDBH
  • ALXO Strong Buy
  • Analyst Count
  • MDBH 0
  • ALXO 6
  • Target Price
  • MDBH N/A
  • ALXO $14.20
  • AVG Volume (30 Days)
  • MDBH 11.0K
  • ALXO 886.3K
  • Earning Date
  • MDBH 11-12-2024
  • ALXO 11-07-2024
  • Dividend Yield
  • MDBH N/A
  • ALXO N/A
  • EPS Growth
  • MDBH N/A
  • ALXO N/A
  • EPS
  • MDBH N/A
  • ALXO N/A
  • Revenue
  • MDBH $1,937,885.00
  • ALXO N/A
  • Revenue This Year
  • MDBH N/A
  • ALXO N/A
  • Revenue Next Year
  • MDBH N/A
  • ALXO N/A
  • P/E Ratio
  • MDBH N/A
  • ALXO N/A
  • Revenue Growth
  • MDBH N/A
  • ALXO N/A
  • 52 Week Low
  • MDBH $5.78
  • ALXO $1.19
  • 52 Week High
  • MDBH $13.25
  • ALXO $17.83
  • Technical
  • Relative Strength Index (RSI)
  • MDBH 61.77
  • ALXO 47.30
  • Support Level
  • MDBH $6.51
  • ALXO $1.19
  • Resistance Level
  • MDBH $9.42
  • ALXO $1.63
  • Average True Range (ATR)
  • MDBH 0.65
  • ALXO 0.11
  • MACD
  • MDBH 0.31
  • ALXO 0.01
  • Stochastic Oscillator
  • MDBH 63.46
  • ALXO 50.00

About MDBH MDB Capital Holdings LLC common

MDB Capital Holdings LLC is an investment holding company that operates through its subsidiaries focuses on early-stage technology companies through public offerings. The company's purpose is to engage with companies holding visionary technology, inventors, and technology entrepreneurs. The Company operates in two reportable segments: a broker dealer & intellectual property service, and the technology development segment. The broker dealer & intellectual property service segment which derives key revenue, is engaged in conducting private and public securities offerings and offers in-depth patent research used for investment banking due diligence.

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: